ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
NCNA Company Profile and Key Details
NuCana
Price Chart
Stock Price Today
NuCana plc (NCNA) stock declined over -5.77%, trading at $0.05 on NASDAQ, down from the previous close of $0.05. The stock opened at $0.05, fluctuating between $0.05 and $0.05 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
Annual Report (10-k)
Stock Price History Chart
Contact Details
About Company
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Company Information
| Employees | 20 |
| Beta | 1.25 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Company Sec.
Prof. Christopher B. Wood FRCS, M.D., Ph.D.
Chief Medical Officer
Mr. Hugh Stephen Griffith
Founder, Chief Executive Officer & Executive Director
Mr. Donald Munoz
Chief Financial Officer
Mr. David Harrison
Head of Translational Medicine
Ms. Theresa Bruce
Senior Vice President of Clinical Operations
Ms. Elisabeth Oelmann
Senior Vice President of Medical & Clinical Devel.
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.
Chief Medical Officer
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep